ArticleNature communications2021
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 2 pooled it
24.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 2 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- Polyphenol-Enriched Composite Bone Regeneration Materials: A Systematic Review of In Vitro Studies.International journal of molecular sciences · 2022Pooled it
- Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review.International journal of molecular sciences · 2021Pooled it
- 3D Electron Diffraction Elucidates the Structure of a 1,3,5-Triazin-2,4-dione Cinnamamide Covalent Inhibitor of SARS-CoV‑2 3CLACS omega · 2026Article
- A Novel Covalent Inhibitor Fragment for the SARS-CoV-2 Main Protease Identified by Target-Specific Deep Learning.ACS chemical biology · 2026Article
- A multi-target drug design method based on target feature fusion.BMC bioinformatics · 2026Article
- Luteolin reprograms macrophage polarization via the STING-TBK1 pathway to accelerate bone repair.Acta biochimica et biophysica Sinica · 2026Article
- Uncovering the covalent inhibitors of SARS-CoV-2 MJournal of pharmaceutical analysis · 2026Article
- Main Protease From SARS-CoV-2 Dysregulates Glucose Handling in the C2C12 Cell Line In Vitro: A Mechanistic Study.Immunity, inflammation and disease · 2026Article
- Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Discovery of Galloyl-Flavonoid Conjugates as SARS-CoV-2 3CLInternational journal of molecular sciences · 2025Article
- Salt Cocrystallization-A Method to Improve Solubility and Bioavailability of Dihydromyricetin.Pharmaceutics · 2025Article
- Generative adversarial network (GAN) model-based design of potent SARS-CoV-2 MMolecular diversity · 2025Article
- Article
- Myricetin-bound crystal structure of the SARS-CoV-2 helicase NSP13 facilitates the discovery of novel natural inhibitors.Acta crystallographica. Section D, Structural biology · 2025Article
- Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds.International journal of molecular sciences · 2025Review
- SARS-CoV-2 Main Protease Inhibitors from Natural Product Repository as Therapeutic Candidates for the Treatment of Coronaviridae Infections.Current medicinal chemistry · 2025Review
- The PGAM5-NEK7 interaction is a therapeutic target for NLRP3 inflammasome activation in colitis.Acta pharmaceutica Sinica. B · 2025Article
- Advancements in Structural Basis of Covalent Inhibitors Targeting SARS-CoV-2 Essential Proteins.Current medicinal chemistry · 2025Review
- Targeting SARS-CoV-2 main protease: a comprehensive approach using advanced virtual screening, molecular dynamics, and in vitro validation.Virology journal · 2024Article
- Design, synthesis, and biological activity evaluation of dihydromyricetin derivatives against SARS-CoV-2-Omicron virus.Journal of enzyme inhibition and medicinal chemistry · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 2 countries.
Haixia Su *CAS Key Laboratory of Receptor Research, and Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0002-7174-3851
Sheng Yao *University of Chinese Academy of Sciences, Beijing, China.
Wenfeng Zhao *CAS Key Laboratory of Receptor Research, and Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0003-2517-4747
Yumin Zhang *State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.ORCID 0000-0003-0767-1221
Jia Liu *University of Chinese Academy of Sciences, Beijing, China.ORCID 0000-0002-8167-9750
Qiang Shao *CAS Key Laboratory of Receptor Research, and Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Qingxing WangUniversity of Chinese Academy of Sciences, Beijing, China.ORCID 0000-0003-1028-1267
Minjun LiShanghai Synchrotron Radiation Facility, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.
Hang XieCAS Key Laboratory of Receptor Research, and Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Weijuan ShangState Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Changqiang KeState Key Laboratory of Drug Research, and Natural Products Chemistry Department, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Lu FengState Key Laboratory of Drug Research, and Natural Products Chemistry Department, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xiangrui JiangCAS Key Laboratory of Receptor Research, and Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jingshan ShenCAS Key Laboratory of Receptor Research, and Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0001-9679-9934
Gengfu XiaoUniversity of Chinese Academy of Sciences, Beijing, China.
Hualiang JiangCAS Key Laboratory of Receptor Research, and Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0003-0656-6315
Leike ZhangUniversity of Chinese Academy of Sciences, Beijing, China. zhangleike@wh.iov.cn.ORCID 0000-0002-2593-2571
Yang YeUniversity of Chinese Academy of Sciences, Beijing, China. yye@simm.ac.cn.ORCID 0000-0003-1316-5915
Yechun XuCAS Key Laboratory of Receptor Research, and Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. ycxu@simm.ac.cn.ORCID 0000-0002-1581-6155
Chinese Academy of Sciences · CNShanghai Institute of Materia Medica · CNWuhan Institute of Virology · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) urgently needs an effective cure. 3CL protease (3CL
Indexed as
Antiviral AgentsCoronavirus 3C ProteasesCoronavirus Papain-Like ProteasesCOVID-19 Drug TreatmentDrug DesignFlavonoidsHEK293 CellsHumansKineticsLigandsMolecular Dynamics SimulationProtease InhibitorsPyrogallolSARS-CoV-2Viral Nonstructural Proteins3C-like protease, SARS coronavirusAntiviral AgentsCoronavirus 3C ProteasesCoronavirus Papain-Like ProteasesFlavonoidsLigandsmyricetinpapain-like protease, SARS-CoV-2Protease InhibitorsPyrogallolViral Nonstructural Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.